Research

Mixed

Switching from continuous full-dose GLP-1/IM therapy to a lower-cost, less effective alternative weight-maintenance program after reaching a weight-loss plateau generates substantial lifetime healthcare savings with only minimal reductions in quality-adjusted life years (QALYs).

If you have successfully lost weight using GLP-1 medications (like Wegovy or Ozempic) and your weight has stabilized, discuss with your doctor whether switching to a lower-cost maintenance strategy (such as a lower dose, a different medication, or a focus on lifestyle/nutrition support) is appropriate for you. This approach may save you significant money and reduce side effects while maintaining a substantial portion of your health benefits, with the option to return to full-dose therapy if you regain weight.

ModerateQualifiesMEDIUM confidence
Our model suggested that, compared with continuous long-term full-dose GLP-1 receptor agonists or incretin mimetic drugs, the alternative weight-maintenance program would generate slightly fewer clinical benefits while generating substantial savings in lifetime health care spending.
David D. Kim et al. · Health Affairs Scholar · 2024

Why this rating

Based on a validated microsimulation model (DOC-M) using trial data, but relies on assumptions about the effectiveness of the 'alternative program' which is not a single standardized intervention.

Source

Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program

David D. Kim et al. · Health Affairs Scholar · 2024

DOI 10.1093/haschl/qxae055

unknown · n=134000000Cited 20×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →